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Abstract
Background and Objectives: Acne scars are one of the most distressing and long‐
term consequences of acne vulgaris, with damaging effect on a person's physical,
mental, and social well‐being. Numerous treatment options are available including surgical and nonsurgical techniques, depending on the clinical presentation. Although considerable advances in the development of new treatment
technologies and applications have been made in the last decade, international
treatment guidelines and reimbursement schemes have not yet caught up with
current knowledge and practice in many centers. The authors intend to highlight
the potential utility of energy‐based devices (EBDs) for acne scarring, offer recommendations for safe and efﬁcacious treatment, and provide consensus‐based
EBD treatment options based on varying presentations demonstrated in a series
of real‐life clinical photographs.
Study Design/Materials and Methods: An international panel of 24 dermatologists
and plastic surgeons from 12 different countries and a variety of practice backgrounds was self‐assembled to develop updated consensus recommendations for the
treatment of acne scars. A two‐step modiﬁed Delphi method took place between
March 2020 and February 2021 consisting of two rounds of emailed questionnaires.
The panel members approved the ﬁnal manuscript via email correspondence.
Results: The manuscript includes a comprehensive discussion and panel recommendations regarding the following topics: 1. the role of EBD in mitigating and treating acne scars in a patient with active acne, 2. the use of
various EBDs for the treatment of different acne scar types with special focus
on commonly used laser platform such as vascular lasers, ablative fractional
lasers (AFLs) and non‐AFLs (NAFLs), 3. treatment combinations, and 4.
acne scar treatments in skin of color. The last part comprised of 10 photos of
real‐life clinical cases with the panel recommendation treatment plan to
achieve best aesthetic outcome.
Conclusion: Panel members were unanimous in their view that EBDs have a role
in the management of acne scars, with AFLs, NAFLs, vascular lasers, and RF
devices preferentially selected by most of the panel experts. EBDs are considered
a ﬁrst‐line treatment for a variety of acne scar types and patients without access to
these treatments may not be receiving the best available care for optimal cosmetic
results. Future high‐quality research and updated international treatment
guidelines and reimbursement schemes should reﬂect this status.
KEYWORDS
acne scars, energy based devices, lasers

INTRODUCTION
Acne is one of the most common and troublesome inﬂammatory skin diseases encountered by dermatologists.
The disorder typically begins at puberty, affecting
95%–100% of adolescent boys and 83%–85% of adolescent girls, and persists into adulthood in approximately
12%–14% of cases.1,2 One of the most distressing and
long‐term consequences of acne is scarring, affecting up
to 95% of patients, with 30% categorized as severe.3,4
Acne scars are not only aesthetically displeasing but can
also result in a signiﬁcant social and societal burden.
They have been described as a risk factor for a variety of

psychological sequelae including suicide, depression,
anxiety, poor self‐esteem, as well as social impairment,
low academic performance, and unemployment.5,6 The
pathophysiology driving acne scar development is attributed to an altered wound healing response initiated
by cutaneous inﬂammation, leading to an imbalance in
matrix degradation and collagen biosynthesis.7 The ultimate severity is correlated with acne grade and delay in
treatment of active disease.8 The end result is either an
excess of collagen that manifests as hypertrophic/keloid
scars or, more commonly, decreased collagen deposition
that manifests as atrophic acne scars in 80 to 90 percent
of cases.3
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Jacob and colleagues have described a classiﬁcation
system to categorize atrophic acne scars into three basic
types: icepick, rolling, and boxcar. Among atrophic scars,
the ice pick type represents 60%–70%; the boxcar type
20%–30%; and the rolling type 15%–25%.9 According to
the qualitative scarring grading system proposed by
Goodman and Baron, a macular acne scar type also
exists, which clinically shows erythematous, hyperpigmented, or hypopigmented ﬂat marks.10 These three scar
types are usually seen in the same person, often making it
difﬁcult to differentiate between them.11 On one hand,
this classiﬁcation system has allowed a consistent and
standardized deﬁnition of acne scars that has been
adopted into clinical research and has aided in treatment
regimens.12 On the other hand, clinical assessment of
scars demonstrates signiﬁcant variation between assessors,13 and the lack of a universally accepted quantitative
or qualitative scoring system makes it difﬁcult to compare treatments for scarring.
Treatment options for acne scars depend on the clinical presentation and include surgical (e.g., excision, subcision, punch techniques) and nonsurgical approaches
(e.g., dermabrasion, needling, chemical peels, injectable
ﬁllers, and energy‐based devices).14 Various factors, including color, depth, and morphology, can affect the
treatment choice for each individual scar,15 and a combined modality approach may produce more beneﬁt
compared with a single modality. Although considerable
advances in the development of new treatment technologies and applications have been made in the last decade,
there is a paucity of high‐quality clinical studies supporting many of these therapies and combinations. The results
of a 2016 Cochrane review failed to provide sufﬁcient
evidence to support the ﬁrst‐line use of any intervention in
the treatment of acne scars. Moreover, the relative safety
of the different interventions as monotherapies or in
combination had not been adequately determined, and
there were no randomized controlled trials (RCTs) to
deﬁne the gold standard treatment against which other
approaches should be measured.16
In light of these challenges, a multidisciplinary
panel of international experts in scar management was
assembled to generate treatment recommendations
based upon available literature and expert opinion. A
similar effort by the same group was undertaken for
traumatic scars in 2020.17 Our goals are to highlight
the potential utility of energy‐based devices (EBDs,
e.g., lasers and radiofrequency [RF]) for acne scarring,
offer recommendations for safe and efﬁcacious treatment, and provide consensus‐based EBD treatment
options based on varying presentations demonstrated
in a series of real‐life clinical photographs. Due to a
greater footprint in the literature, the focus of this
manuscript will be on laser devices, with RF forming a
minor part of the discussion. Other devices, while
promising, are not yet well‐represented in the
literature.
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An international panel of 24 dermatologists and plastic
surgeons was self‐assembled to develop updated consensus recommendations for the treatment of acne scars.
The panel members represented a broad range of experience in academic, private practice, and hospital‐
based settings from 12 different countries. Four authors
(F.S., O.A., P.S., and G.G.) curated the initial clinical
questions based on panel input and literature review. A
two‐step modiﬁed Delphi method was implemented between March 2020 and February 2021. The Delphi
method is an iterative process used to achieve consensus
for a deﬁned clinical problem where there is little or
conﬂicting published evidence and where expert opinion
is decisive.18 Our modiﬁed Delphi method consisted of
two rounds of email questionnaires in which the following topics were highlighted:
1. The role of EBD in mitigating and treating acne scars
in a patient with active acne.
2. The use of various EBDs for the treatment of different
acne scar types.
3. Treatment combinations including EBDs.
4. Considerations in skin of color.
The last part of the questionnaire was comprised of
10 photos of real‐life clinical cases in which each panelist
offered his/her recommended treatment plan to achieve
best aesthetic outcome.

The role of EBD in mitigating and treating acne
scars in a patient with active acne
The coexistence of active inﬂammatory acne lesions and
acne scars poses both a challenge, and an opportunity, in
timely management of acne scarring. Time between acne
onset and ﬁrst effective treatment was found to be a risk
factor for developing acne scars.19 While most patients
are treated solely with topical and/or systemic antiacne
medication, prior studies have shown that a range of
EBD including intense pulsed light (IPL), diode, 585/
595 nm pulsed dye laser (PDL), 532 nm potassium titanyl
phosphate (KTP) lasers, several infrared lasers, including
the 1550 nm erbium glass, 1064 nm and 1320 nm
Nd:YAG lasers, and ﬂuorescent light treatment may also
be effective in treating moderate‐to‐severe acne.20–25 The
proposed mechanism of action is through reduction of
Propionibacterium acnes (P. acnes) levels, disruption of
sebum production, and reducing inﬂammation.25–27 Laser therapies are likely to offer the greatest beneﬁt to acne
vulgaris patients when used in conjunction with medical
therapy,28 and literature on their efﬁcacy is growing rapidly. There is increasing evidence for the effectiveness of
fractional radiofrequency (FRF) microneedling in the
treatment of active acne, either as sole treatment29,30 or

4

|

in combination with other EBDs, such as carbon dioxide
(CO2) lasers.31 FRF was found to be effective in decreasing the number of acne lesions (inﬂammatory and
noninﬂammatory) and sebum excretion.

EBDs and isotretinoin
Patients with nodulocystic and severe acne who are on,
or have recently completed, isotretinoin are also highly
likely to be among those who would beneﬁt from intervention with EBD to mitigate scarring. Isotretinoin
(13‐cis‐retinoic acid) is a metabolite of vitamin A that
is approved by the FDA for treating severe acne, acne
unresponsive to other treatments, and cases in which
other treatments would be likely to leave scars and
have negative emotional effects.32 It has demonstrated
beneﬁt in patients with severe acne resulting in
numerous effects including involution of the pilosebaceous unit, decreased acne lesions and related scarring, and a decrease in associated symptoms of anxiety
and depression.33–36
For decades dogma has held that patients who are
on, or are within 6 to 12 months of completing, a course
of isotretinoin should avoid most cutaneous procedures
due to a concern for heightened risk of delayed wound
healing and raised dermal (hypertrophic/keloid) scarring
in the context of decreased healing potential from diminution of the pilosebaceous apparatus. Interestingly,
this expansive and durable recommendation was based
largely on a relatively small number of case reports from
the 1980s, primarily involving mechanical dermabrasion.37 This topic received a re‐examination in 2017 with
the publication of two seminal consensus documents,
including one published under the auspices of the
American Society for Dermatologic Surgery (ASDS).38,39
Only three prior reports of abnormal scarring after laser
procedures within 6 months of isotretinoin were found
on literature review, including one argon laser, one fully
ablative Er:YAG, and one pulsed dye laser treatment.
The ASDS task force concluded that there was insufﬁcient evidence in the literature to justify delaying
treatment with hair removal devices, vascular lasers, non‐
ablative fractional lasers (non‐AFL), and AFL in patients receiving, or who have received, isotretinoin within
the last 6 months. They also recommended that fully
ablative (i.e., non‐fractionated) treatments should generally be avoided until 6 months after the completion of
isotretinoin in accordance with traditional practice.
The consensus panel that authored the JAMA
Dermatology article came to similar conclusions and
indicated that avoiding procedural intervention for
6–12 months after completing isotretinoin conﬂicts
with current trends toward early intervention for
scarring, and effectively delays treatment for a condition with signiﬁcant physical and mental sequelae.39
Results of a provider survey on procedures in the
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context of isotretinoin indicated that while a small
majority of respondents recommended patients wait at
least 6 months or longer after completing isotretinoin
therapy before receiving laser and light‐based treatment, 70% reported that primarily medicolegal concerns guided their treatment decisions.40 Since 2017
multiple studies have found various EBD including
vascular lasers, non‐AFL, and 1064‐nm lasers safe and
effective for acne and acne scarring either in combination with isotretinoin or starting within 1 month of
completing isotretinoin.41–44

Panel recommendations: EBD for mitigating
and treating acne scars in a patient with
active acne
• Seventy‐four percent of panel members indicated that
patients with active acne and acne scars should be
treated with EBD and topical or systemic medications
in parallel. The proposed rationale for using EBD was
reducing the severity and/or duration of inﬂammation
and scarring potential (98% of the panelists) and enhancing the effectiveness of topical or oral medication
(54% of the panelists).
• The most prominent considerations for the use of EBD
in the treatment of active acne were:
◦ Poor candidates for oral medication (e.g., pregnancy, mental health issues, etc.) (94% of panelists).
◦ Presence of existing scars (75%).
◦ Elevated risk of scarring in the context of active
inﬂammatory lesions (69%).
• Vascular lasers were the preferred EBD in the management of inﬂammatory acne (80%) of panelists.
◦ Seventy‐ﬁve percent of panelists use 595‐nm PDL.
Three to ten milliseconds was the preferred pulse
width for the majority of panelists (67%). The preferred settings for 595‐nm PDL ranged between 7
and 10 mm, 3–10 milliseconds, 6.5–10 J/cm2, with the
minority of responders choosing settings for shorter
pulse durations of 5–10 mm, 0.45–1.5 milliseconds,
5–9 J/cm2.
◦ Fifty percent of panelists use the 1064‐nm Nd:YAG.
This wavelength may be preferable for patients with
darker skin types due to decreased melanin absorption, or for hypertrophic scars due to greater depth
of penetration.
◦ Other devices used by panel members for inﬂammatory acne management were AFL and
NAFL (25% of panelists) and FRF (20%).
◦ Most panel experts (82%) indicated that parallel
treatment with vascular, AFL, or NAFL and oral
antibiotics can have a positive synergistic effect on
inﬂammatory acne.
◦ The majority of panelists (82%) indicate that EBDs
may be safely used concurrently with isotretinoin in
the appropriate setting.
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◦ Thirty‐three percent of panelists indicated there
may be a synergistic anti‐inﬂammatory and anti‐
scarring effect with combined treatment.
◦ Most panelists (80%) selected vascular lasers as their
preferred EBD for patients who were being treated
with isotretinoin. Approximately three‐fourths reported the need for adjusting vascular laser settings
including decreasing the pulse energy and number of
passes in the setting of isotretinoin use.
◦ Sixty percent and forty ﬁve percent of the panelists
supported the use of NAFL and AFL, respectively, during isotretinoin treatment. For those
who would not use AFL while on isotretinoin,
there was an even split between those advocating
waiting 1–5 months and 6 months or more after
cessation.

Conclusions and areas of future study
• It is clear that EBDs are regularly utilized by experts
for treating active inﬂammatory acne, with vascular
lasers the clear choice among panel members. Additional studies are required to conﬁrm individual platforms and comparative efﬁcacy with potential
mechanisms of action and safety issues, including the
potential of acne ﬂares in active acne patients treated
with AFL and NAFL. Combining EBD and medical
therapy (topical and systemic) for active acne is fertile
ground for new research.
• There is consensus among the panel members that
selected EBDs, particularly vascular lasers, may be
used safely in combination with isotretinoin treatment.
It is important to consider that there is a continuum in
cumulative thermal injury, and likely relative associated risks, among devices progressing from vascular
lasers, to NAFL, AFL, and ﬁnally fully ablative “full‐
ﬁeld” lasers. Given the impact of acne scarring on the
overall psychosocial as well as quality of life, a new
more inclusive treatment paradigm is required. Indeed,
early intervention with EBDs should be adopted and
informed consent should include a discussion of these
options. To this end, additional research conﬁrming
safety and efﬁcacy for each platform in the setting of
isotretinoin is required, in addition to determining the
presence or absence of a synergistic response.

The use of various EBDs for the treatment of
different acne scar types
EBDs, primarily lasers and FRF, have emerged as a
noninvasive option for the treatment of acne scars in the
last decade.45 Controlled thermal and non‐thermal (e.g.,
Picosecond lasers) injury to the epidermis/dermis stimulates extracellular matrix remodeling, production of
collagen and elastin, and, depending upon the selected
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laser wavelength, reduction of dyspigmentation and
erythema.46–48
Panel members are unanimous in their view that
EBDs have a role in the management of acne scars, with
AFLs, NAFLs, vascular lasers, and RF devices preferentially selected by 70%–90% of the panel experts due
to their perceived efﬁcacy, familiarity, and footprint in
the literature. Selection of the most appropriate device
and setting are highly nuanced decisions inﬂuenced by a
variety of factors including the clinical presentation (e.g.,
skin type, scar location, and morphology, etc.), characteristics of the device (e.g., wavelength and targeted
chromophore, depth of penetration, etc.), and patient
factors such as goals, tolerance for discomfort and
downtime, and ﬁnancial considerations. Previous comparative studies have shown that severe atrophic scars
respond better to ablative lasers, such as CO2 and
Er:YAG, whereas mild‐to‐moderate atrophic scars can
be treated with less invasive modalities, such as NAFL
and RF devices.49 The variability in response to treatment between different scar types derives from the pathological structure of each scar, including collagen loss
and the degree of ﬁbrosis and anchoring ﬁbrous bands.

Panel recommendations: Device and settings
selection
• The most important factors that inﬂuenced EBD selection were the type (e.g., boxcar, ice pick, rolling)
and site (i.e., face, off‐face) of acne scarring (77% of
panelists). Interestingly Fitzpatrick skin type and severity of scarring were less inﬂuential among panelists
(56% and 43%, respectively). One factor may be the
relative tolerability of fractional devices for the entire
range of skin types given the water chromophore
(AFL, NAFL) and degree of epidermal sparing (FRF).
• EBDs were considered a ﬁrst‐line treatment of acne
scars for the following scar types: macular dyscoloration (95%); mild atrophic scarring (i.e., rolling scars,
73%); and moderate atrophic scarring (i.e., superﬁcial
boxcar scars, 78%).
• For atrophic acne scars, panelists selected superﬁcial
boxcar scars (91%) as the most likely to respond to
EBD treatment. AFL was the most common EBD of
choice for boxcar scars (62%). Table 1 highlights the
selected platforms for each acne scar subtype.
• In consideration of the anticipated degree of maximal
improvement after the completion of a typical treatment course with EBD devices:
◦ AFL 51%–70% improvement.
◦ NAFL and RF devices 31%–70% improvement.
◦ Vascular devices 31%–>70% improvement (in
erythema).
• Six months after the ﬁnal treatment was selected by
most panelists as the appropriate interval for evaluating the efﬁcacy of a course of EBD therapy for acne
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TABLE 1
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Platforms used according to scar type and color

To note: Each panelist could choose multiple devices for each scar
type
1. Deep atrophic scars: AFL (85%), FRF (25%), subcision (25%),
and NAFL (18%).
2. Shallow atrophic scars: AFL (72%), NAFL (68%), and
RF (12%).
3. Hypertrophic scars: AFL (56%), pulsed dye laser (PDL, 47%),
laser‐assisted delivery (LAD, 31%), and intralesional injection of
TAC/5‐FU (22%).
4. Flat erythematous scars: PDL (85%), 532 nm laser (25%), NAFL
(18%), and ms‐pulsed 1064 nm laser (12%).
5. Patients with dark skin: NAFL (66%), PDL (18%), FRF devices
(18%), Nd:YAG (12%).
6. Hyperpigmented scars or post‐inﬂammatory
hyperpigmentation: picosecond Nd:YAG lasers (57%)
Q‐switched laser mostly Nd:YAG (33%) and NAFL (20%) and
AFL (13%)

scars. Almost all (95%) would continue laser therapy
according to patient preference if there were no contraindications and if the condition continued to improve, rather than adhere to a predetermined number
of treatments.
• The most common selected setting combinations for a
typical atrophic acne scars were high energy and low‐
moderate density for AFL (Table 2), NAFL, and
FRF. For deeper scars, the vast majority (87%) of
panelists would increase the energy setting of their
devices.
• The most common method for evaluating efﬁcacy after
a treatment course with EBD was photographic evaluation (48%). Only 21% routinely employed scales
(e.g., Vancouver Scar Scale [VSS], Patient and Observer Scar Assessment Scale [POSAS], Manchester
Scar Scale [MSS], Global Aesthetic Improvement
Scale [GAIS], Goodman Baron qualitative).

AFL in the treatment of acne scars
Ablative fractional lasers take advantage of high
absorption of associated wavelengths (i.e., 2940 nm
Er:YAG and 10,600 nm CO2) by ubiquitous tissue water
to generate an array of narrow columns of vaporization
and varying degrees of surrounding coagulation. This
controlled thermal injury induces a vigorous wound
healing and remodeling response in the area of treatment. By targeting tissue water rather than melanin,
AFL may be employed in a wide range of skin types.
Since absorption by water at the 2940 nm wavelength is
approximately 10 times the absorption at 10,600 nm,
there is less heat diffusion and consequently a narrower
rim of surrounding coagulation. This characteristic can
be associated with more treatment‐related bleeding and
possibly more moderate remodeling results compared to
CO2.47,50–52

T A B L E 2 Relative density and pulse energy settings for a common
ablative fractional laser platform in treating acne scars (Lumenis
UltraPulse™, Deep FX™, Yokneam, Israel)
(1) Pulse energy
I. High: >30 mJ (>0.9 mm ablation depth, use only with low
density).
II. Moderate: 15–30 mJ (0.45–0.9 mm ablation depth, use only
with low or moderate density).
III. Low: <15 mJ (<0.45 mm ablation depth, software only
supports use with moderate density).
(2) Density
I. High: ≥15% (use with caution, and only with low pulse energy).
II. Moderate: 10%.
III. Low: ≤5%.

Panel recommendations: Ablative fractional
laser in the treatment of acne scars
• Forty‐seven percent of panelists indicated that the
fractionated CO2 laser is more effective than the
fractionated Er:YAG for acne scarring, while 8%
thought the opposite. The remainder indicated that
additional research is required.
• A majority of panelists (65%) indicated that AFL is a
more effective platform for treating rolling and superﬁcial boxcar acne scars than NAFL, while 8% had
the opposite view.
• Most panelists (73%) agreed that a series of AFL
treatments are more effective in treating rolling and
superﬁcial boxcar acne scars than a single phenol peel
or fully ablative CO2 laser treatment.
• A large majority of panelists (95%) expected to perform a series of 2–4 AFL treatments to achieve a satisfactory clinical response.
◦ The preferred interval between AFL treatments for
43% of the respondents was 2–3 months, 26% and 21%
preferred 1 month and 4–6 months, respectively.
◦ A variety of commercially available fractional ablative CO2 lasers are available, but panelists agreed
that in order contextualize settings it was important
to establish a known platform as a reference. The
parameters offered in Table 2 pertain to the Lumenis UltraPulse™ (Yokneam, Israel) Deep FX/
SCAAR FX™. Settings for other devices can be
extrapolated based on individual characteristics and
manufacturer recommendations. Of course, individual patient considerations (e.g., skin type, pain
tolerance, etc.) will dictate setting selections in any
given treatment session.
• The majority of panelists favored moderate‐to‐high
pulse energy and low‐to‐moderate density in the acne‐
scared area with some feathering for the remainder of
the cosmetic unit.
• Some panelists endorsed judicious application of a second
superﬁcial pass of macro‐fractional treatment (Active
Fx™) at a pulse energy of 90–125 mJ and density 3–4,
1.3 mm spot size over the entire cosmetic unit.
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NAFL for the treatment of acne scars
Non‐ablative fractional skin remodeling systems, such as
the 1550‐nm Er:glass and 1565‐nm ﬁber lasers, have become increasingly popular for the treatment of atrophic
acne scars due to a perception of increased tolerability (i.e.,
darker skin types) and decreased associated downtime of
1–2 days compared to 1–2 weeks for ablative systems.53
Since water is the target chromophore without absorption
by epidermal melanin, NAFLs may be considered in the
full range of skin types. NAFLs were the ﬁrst variety of
fractional lasers and were designed to create narrow (submillimeter) and widely spaced columnar thermal wounds at
a depth and density selected by the operator. This pattern
allows treatment at sufﬁcient depths for robust remodeling
while minimizing damage to the epidermis and diffuse
dermal injury.50,54 This combination theoretically offers a
decreased risk of side effects such as erythema, edema,
crusting, infection, and worsening scarring compared to
AFL.55,56 However, this greater margin of safety for NAFL
is also likely associated with a need for more treatments
and a lower ceiling for overall efﬁcacy compared to AFL.57

Panel recommendations: NAFL in the treatment
of acne scars
• The preferred interval between NAFL treatments was
1 month by 60% of the respondents.
• Most panelists (90%) expect to perform 4–8 NAFL
treatments to achieve a satisfactory clinical response.
• The preferred standard settings for NAFL in the
treatment of atrophic acne scars were moderate to high
pulse energy and low to moderate density.
• NAFL may be the preferred choice for patients with
more moderate acne scarring, a lower tolerance for
downtime, darker skin types, and mature non‐
erythematous scars since efﬁcacy is not dependent on
hemoglobin.

Vascular lasers for the treatment of
erythematous acne scars
Vascular devices emit wavelengths that are absorbed by
hemoglobin which demonstrates peaks at 542 and 577 nm
for oxyhemoglobin. These devices, such as the 595 nm PDL,
selectively heat vascular components of the dermis. In addition to treating scar‐associated erythema, vascular lasers
also induce a wound‐healing and collagen remodeling response via key mediators involved in scar formation such as
the transforming growth factor‐β isoforms.57,58 Successful
treatment usually requires 3 or more treatments given at
approximately 1‐month intervals. Since shorter vascular
wavelengths are also absorbed to a signiﬁcant extent by
epidermal melanin, patients with darker skin types may not
be suitable candidates for these devices.

|
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Panel recommendations: Vascular lasers in the
treatment of acne scars
• Erythema is often the most pronounced ﬁnding in
patients with acne scarring so vascular lasers can play
an important role in their overall management.
• Importantly, erythema is a characteristic of early acne
scars including future atrophic and hypertrophic acne
scars. As such, early intervention with vascular devices
may help to minimize incipient pathological scars.
• Sixty‐ﬁve percent of panelists selected erythematous
ﬂat acne scars as the scars most likely to respond to
EBD treatment alone, and 95% indicated that EBDs
are a ﬁrst‐line treatment for these scars.
• The 595 nm PDL was the most frequently selected
vascular device among panelists due to its familiarity
and footprint in the literature. However, other vascular devices such as the 532 nm KTP and intense
pulsed light may also be employed.
• Panelists were divided into two major groups with regard to PDL settings. One group advocated medium‐
length pulse durations and somewhat higher ﬂuences
(7–10 mm; 6–10 J/cm2; 6–10 milliseconds) and the other
shorter pulse durations and somewhat lower ﬂuences
(5–12 mm; 4.5–6 J/cm2; 0.45– 1.5 milliseconds).
• Vascular lasers were the EBD of choice among panelists
for hypertrophic acne scars. PDL was the preferred
vascular‐speciﬁc laser for 77% of panelists, who also tended to use shorter pulse durations in this setting.
• More than 95% of the respondents indicated the need
for at least 3–6 vascular laser sessions for typical erythematous hypertrophic acne scars.

Short‐pulsed (nanosecond and picosecond) lasers
for the treatment of acne scars
The Q‐switched (nanosecond) Nd:YAG 1064 nm laser is a
mature technology that is associated with relatively deeper
dermal penetration than other platforms and photomechanical as well as photothermal effects.59 Published reports indicate that the Nd:YAG provides a safe and effective
noninvasive treatment for mild‐to‐moderate facial acne
scarring,60,61 though less effective than the fractional CO2 for
atrophic acne scarring.62 These devices may also have a role
for post‐inﬂammatory hyperpigmentation.
Introduced in 2012, picosecond lasers were originally
designed to remove tattoos and other pigments with small
particle sizes. The ultra‐short pulse durations create signiﬁcant photoacoustic as well as photothermal effects.
Later iterations incorporated a diffractive lens array which
redistributes the laser beam into peaks of high ﬂuence
surrounded by a low ﬂuence background, thus creating
optical breakdown of dermal tissue and the induction of a
wound healing and remodeling response with neocollagen
formation. Several published reports have demonstrated
mild to moderate clinical effectiveness for atrophic acne
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scarring with a very low side effect proﬁle and corresponding histologic changes.63–70 Two prospective, split‐
face, randomized controlled trials compared the 1064 nm
Nd:YAG picosecond laser to the non‐ablative 1550 nm
erbium‐glass laser. One found the picosecond laser to be
superior in terms of both efﬁcacy and safety,69 while the
other was inconclusive.70 Of note differences in the reported
outcomes might be partly explained by the different laser
settings used in the two studies. Picosecond lasers may
also have a prominent role in the treatment of post‐
inﬂammatory hyperpigmentation.

Panel recommendations: Short‐pulsed lasers for
the treatment of acne scars
• As may be expected, short‐pulsed lasers were the
EBD of choice among panelists for macular hyperpigmentation associated with acne, both in fractional and non‐fractional modes.
• The novel effects produced by picosecond lasers are
promising for improvement in both the atrophy and
hyperpigmentation that follow acne, but additional
research is required to elucidate any additional beneﬁts
over nanosecond devices as well as the impact of
fractionation.
• Eighty‐six percent of respondents indicated the need
for 3–6 laser treatments with short‐pulsed devices to
achieve a satisfactory result.

FRF
RF is an electromagnetic radiation with a frequency
range between 3 Hz and 300 GHz. In fractional bipolar
RF device, the RF current ﬂows through the skin between the electrode‐pins or microneedles. It generates
fractional deep dermal heating in the region of the electrode matrix to induce skin injury and then elicits a
wound healing response, stimulating the remodeling of
dermal collagen. New developments have allowed for
more precision in the delivery of RF energy to different
desired depths within the dermis.71,72

Panel recommendations: FRF devices for the
treatment of acne scars
• Though there was generally less experience among
panelists with FRF than other laser devices, most respondents (69%) indicated that FRF has a promising
role in the management of atrophic acne scars.
• Most panelists (60%) indicated that microneedling
alone (with no RF) yields inferior results compared to
FRF in the management of atrophic acne scars.
• A small majority of panelists (52%) indicated that the
insulated FRF devices are associated with better

ENERGY‐BASED DEVICES FOR THE TREATMENT OF ACNE SCARS

results compared to non‐insulated FRF devices,
probably due to higher thermal effect along the different dermal layers. Several treatment passes were
considered to have better results than a single pass.
• Additional research is required to show the effects of
multiple‐depth passes and high‐energy FRF for treating acne scars.
• Further clinical research is required to establish the
comparative effectiveness between FRF, NAFL,
and AFL.
• The preferred interval between FRF treatments was
1 month for 60% of respondents, and the average
number of FRF treatments to achieve satisfactory results for atrophic acne scars was 4–8.

Selected non‐laser, non‐RF EBDs in the
treatment of acne scars
A range of other energy‐based devices demonstrate potential utility for the treatment of acne scars. Since there is a
relative paucity of experience with non‐laser, non‐RF devices, only two of the most commonly mentioned devices
will be discussed here. Moreover, additional research will
be required to elaborate their potential respective roles in
the management of acne scarring. The Tixel™ (Novoxel
LTD.) is a non‐laser, fractional, non‐ablative, thermomechanical system based on thermal conduction which
combines thermal energy with motion. The thermal energy
is delivered to the tissue via a tip with tiny titanium pyramids heated to 400°C. The amount of thermal energy
delivered to the skin is determined by the pulse duration
and the protrusion. The pulse duration is the period of time
that the tip is in contact with the skin, varying between 5
and 18 milliseconds. The protrusion is deﬁned as the distance over which the heated tip moves as measured from
the edge of the handpiece distance gauge. The device was
found to be effective in skin rejuvenation,73 hypertrophic
scars,74 and drug delivery.75 Only a minority of panelists
(34%) indicated having experience with this device in the
treatment of acne scars. Among those, most estimated the
expected maximal improvement after a standard course of
treatment to be mild (<20%).
The Enerjet™ (PerfAction Technologies UK Ltd.)
employs pneumatic acceleration of drugs or ﬁllers. It is a
needle‐free jet injector implementing the kinetic energy of
a liquid jet for transcutaneous delivery of drugs or ﬁllers
into soft tissues. It was shown to be effective in treating
keloids and hypertrophic scars via intralesional jet injection of bleomycin, 5‐ﬂuorouracil (5‐FU), and triamcinolone.76,77 Several case reports of this device or similar
technologies also demonstrated efﬁcacy in the treatment
of acne scars.78,79 Among panelists, 39% indicated having experience with this device in the treatment of acne
scars. The estimated expected maximal improvement
after a standard course of treatment was also expected to
be mild (<20%).
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Combination modalities in the management of
acne scars
Since there are such a wide variety of patients presenting with acne scarring of mixed types, a combined
approach to EBD treatment is often considered. This
may include combinations of different EBD platforms, as well as EBDs combined with other treatment approaches such as subcision, excision, and
ﬁllers that may achieve better outcomes than any
single modality alone.45,80 Injectable ﬁllers can be
used to mitigate atrophic acne scars in two ways: direct ﬁlling under individual scars with products such
as hyaluronic acid (HA), and biostimulatory ﬁllers
such as poly‐L‐lactic acid (PLLA) or calcium hydroxylapatite (CaHA) in an area where volume loss
and tissue redistribution has accentuated existing
scars.80,81 Laser‐assisted PLLA delivery82 and FRF‐
assisted PLLA delivery 52 have also been described in
the treatment of atrophic acne scars.

Panel recommendations: Combination of
modalities in the treatment of acne scars
• The vast majority of panelists (95%) combine multiple EBD platforms, and other treatment modalities, in the same treatment session. There is no
“cookbook” or “gold standard” approach here as a
treatment plan is based on multiple factors unique
to an individual patient on a particular day which
includes scar types, co‐existing conditions, prior
treatments and response, skin type, degree of melanization, tolerance for pain, patient compliance
and downtime.
• When EBDs and other modalities are performed in the
same session, frequently the other modalities are employed ﬁrst due to associated skin changes that may
affect landmarks such as post‐EBD erythema and
edema.
• The EBD‐second approach may be particularly beneﬁcial when surgical approaches (e.g., excision) are
considered as EBDs may mitigate the surgical scars as
well as the surrounding acne scars. There was not
signiﬁcant agreement on the timing of surgical approaches and subsequent EBD treatment, ranging
from same session (39%) to 4–6 weeks after the surgical procedure.
• A caveat to the EBD‐second approach may apply to
ﬁllers. A course of EBD (perhaps including subcision)
before ﬁller placement may better prepare the skin to
accept the ﬁller and help mitigate the tendency for ﬁller
to “donut” around a tethered scar. In terms of cost‐
effectiveness for the patient, less ﬁller may ultimately
be required. If one is considering EBD‐assisted delivery of a ﬁller such as PLLA, the fractional device will
naturally be applied ﬁrst to access the dermis.
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• When performing subcision, 65% of panelists will
prefer to subscise the tethering ﬁbers before EBD
treatment at the same session.
• Ice pick scars were considered the type least likely to
respond to EBD. Most experts endorsed surgical
approaches (e.g., punch techniques) or chemical
reconstruction of skin scars (CROSS) using trichloroacetic acid (TCA) ﬁrst followed by EBD, often
in the same session.
• When combining EBDs, most panelists recommended
the combination of PDL and fractional lasers. When
this combination is used, the vascular laser should
generally be applied ﬁrst since fractional lasers are
associated with immediate tissue reactions that could
impact vascular laser treatment. Three‐quarters of
panelists do not adjust EBD settings when using
multiple platforms in the same session, though it is
important to consider tissue response and visual endpoints when choosing EBD settings to minimize the
risk of excessive thermal injury.
• More than 69% of panelists reported using tissue ﬁllers
or biostimulators with EBDs as part of acne scar
treatment. Of these approximately 70% reported a
preference for using HA‐based ﬁllers.
• There was nearly complete consensus (95%) for
combining EBD (mainly PDL) with intralesional
and/or LAD of 5‐FU and/or triamcinolone acetonide suspension (TAC) for treating hypertrophic
acne scars.
• For the treatment of patients with dark skin and/or
hyperpigmented ﬂat macules post‐acne, most of respondents (56%) combine EBD treatment and topical
formulations or peels. The three most selected formulations were hydroquinone 2%–5% (47%), retinoic
acid (35%), and glycolic or salicylic acid (17%). The in‐
ofﬁce formulations are used immediately post‐EBD
treatment.
• Seventy‐three percent of panelists indicated that LAD
has a signiﬁcant potential role in acne scar treatment.
The medications that are most commonly used by the
panelists in combination with ablative fractional lasers
for LAD were corticosteroids (82%) and 5‐FU (56%)
for hypertrophic acne scars and PLLA (43%) for
atrophic acne scars.
• Almost 94% of respondents prescribe different formulations between or before EBD treatments for all
acne scar patients, with 0.01%–0.05% retinoic acid
being the most common formulation (56%).
• Future comparative studies are required to guide the
optimal combinations of EBD and other modalities as
well as timing and settings.

Considerations in skin of color
Hyperpigmentation is a potential complication of any
EBD intervention, especially for patients with darker
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skin phototypes (i.e., IV–VI). The concept of fractional lasers was introduced by Manstein et al. 83
Fractionation has revolutionized the ﬁeld of dermatologic surgery, allowing operators for the ﬁrst time
to choose the depth and density of treatment. By
sparing large areas of adjacent dermis and epidermis,
fractional lasers allow access to deeper dermal levels
with a high degree of safety and efﬁcacy. With water
as the target chromophore, fractional lasers can also
be applied in the full range of skin types.
While these lasers offer a greater theoretical margin
of safety compared to prior platforms, they are not
without side effects. Transient erythema, edema,
dermatitis, acneiform eruptions, outbreaks of herpes
simplex virus and varicella reactivation, and dyspigmentation have all been documented in existing studies.
Post‐inﬂammatory hyperpigmentation (PIH) is more
commonly observed in patients with darker skin types.84
Similarly, FRF offers the beneﬁts of fractionation, but
may also have an additional theoretical margin of safety
due to greater sparing of the epidermis with insulated
needles. As noted vascular devices may not be appropriate in all skin types due to signiﬁcant melanin absorption at associated wavelengths.
Both pulse energy and density are key parameters
that determine the safety and efﬁcacy of fractional
resurfacing in patients with darker skin types, but it
appears that density may play a more important role
in determining the risk of PIH. Regardless of the
platform, patients with darker skin types may require
treatment modiﬁcations including: a reduction in
ﬂuence/pulse energy; decreased microcolumn density;
greater intervals between treatments; longer pulse
durations; epidermal cooling with fastidious technique to ensure appropriate cooling, additional cooling
in between passes to decrease bulk heating; and pretreatment and posttreatment topical regimens (e.g.,
retinoids, bleaching creams, etc.) and strict sun precautions.54 Furthermore, the application of a short
course of topical corticosteroid was found effective in
reducing the risk PIH. 85

Panel recommendations: Consideration in skin
of color
• In patients with darker skin types (Fitzpatrick phototype III–VI) presenting with atrophic boxcar acne
scars, the majority of panel members (77%) selected
NAFL as their preferred EBD. FRF devices were
the next highest choice (39%– some panelists selected both).
• Regarding NAFL parameter modiﬁcations in patients
with darker skin types, almost 70% of panelists
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reported decreasing density; 47% reported increasing
the interval between treatments; 40% reported decreasing the pulse energy.
Almost 60% of panelists reported using adjunctive
medical therapy for patients with darker skin types to
help prevent PIH (e.g., bleaching creams, steroids, etc.)
when treating with NAFLs for patients with darker
skin types.
Regarding AFL parameter modiﬁcations in patients with darker skin types (IV–VI), most panelists (56%) reported that they will increase the
interval between treatments; almost 50% indicated
that they will decrease density; a majority (65%)
favored using adjunctive medical therapy in addition to laser treatment.
NAFL, AFL, and FRF devices are regularly employed by
experts for the treatment of acne scars in patients with
darker skin types. Comparative studies are lacking, and
future research should help match an optimal platform
with the clinical presentation.
For hyperpigmented macules, a large portion of experts favor picosecond lasers. They are a promising
but relatively new technology and future prospective
comparative studies are required to evaluate their efﬁcacy and safety.
The combination of laser and medical therapy (e.g.,
topical agents, chemical peels, etc.) is fertile ground for
new research.

Clinical case examples
The literature is replete with studies evaluating EBD for
acne scarring. However, given the numerous unexplored
treatment options including device and procedure combinations, timing, parameters, and adjunctive therapies,
comprehensive guidelines are currently lacking. To begin
to offer some guidance, panelists were presented a series
of photos representing varying clinical scenarios
and asked to offer their proposed treatment plans
incorporating EBD.
Patient 1: Female, Fitzpatrick skin type 2, erythematous
and mildly atrophic dish‐like scars.
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Agreed upon intervention
Almost 94% of panelists favored a vascular laser, largely
PDL, as the initial treatment (Settings mentioned were
7 mm, 1.5–3 milliseconds or 7–10 mm, 6–10 milliseconds
7–10 J/cm2).
Additional possible measures suggested by some
panelists:
• Combination of PDL with NAFL in the same or alternating treatment sessions.
• FRF
• IPL
• PDL with topical salicylic acid 30%, oral antibiotics, or
low (i.e., 20 mg per week) or high (i.e., 40 mg per day)
dose isotretinoin. Of note rules regulating the use of
isotretinoin vary from country to country.
• NAFL and HA ﬁller once erythema is improved.
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Most panelists favored combining AFL with other interventions including:
• Subscision (43%).
• Filler with HA, CaHA, or PLLA (43%).
• Excisions (17%).
Most experts recommended that subscision should
precede AFL treatment, and that ﬁller treatments be
administered 2–4 weeks after AFL treatment.
Patient 3: Male, Fitzpatrick skin type 3, punched out
deep atrophic scars.

Patient 2: Female, Fitzpatrick skin type 3, deep and
broad atrophic areas.

Agreed upon intervention:
Most panelists (77%) selected AFL as the appropriate EBD.
Additional possible measures suggested by some
panelists:

Agreed upon intervention:
Seventy‐eight percent of panelists preferred using AFL,
Suggested CO2 laser settings (Lumenis UltraPulse Deep
FX™, Yokneam, Israel) included 40–50 mJ, 5% density,
0.12 mm spot size, focal scar treatment, 15–17.5 mJ,
10%–15% density single pass over the scarred cosmetic
area; followed by Active FX 80–125 mJ, density 3–4.

• Combining AFL with a surgical technique (punch
techniques/subcision/excision).
• CROSS TCA combined with AFL.
• NAFL combined with surgical technique.
• FRF devices combined with surgical technique.
• Fillers (including PLLA).
• Enerjet.
Patient 4: Male, Fitzpatrick skin type IV, hyperpigmented and mildly atrophic scars.
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Agreed upon intervention:
Due to PIH tendency, most panelists (74%) agreed on
using a non‐AFL devises, there choices were divided
evenly between NAFL (35%) and AFL (35%).
Additional possible measures suggested by some
panelists:
• Several panelists suggested using a test area before
using AFL.
• Thirty percent favored the combination of a surgical
technique (punch biopsy/subcision/excision) with EBDs.
• Twenty‐one percent panelists favored using topical
bleaching medications, including tretinoin, azelaic
acid, hydroquinone, and Tri‐luma (brand info) cream.
Patient 5: Female, Fitzpatrick skin type II, hypopigmented and mildly erythematous scars.

Agreed upon intervention:
Almost 44% of panelists selected AFL as the appropriate EBD for this case.
Additional possible measures suggested by some panelists:
• NAFL and vascular lasers (mainly PDL) were each
selected by 26% of the panelists.
• EBD combinations (usually vascular laser and AFL)
were also suggested.
• A surgical technique (punch biopsy/subcision/excision)
and ﬁllers (including PLLA) were advised by 17% and
21% of the panelists, respectively.
Patient 7: Female, Fitzpatrick skin type 2, erythematous and mildly atrophic linear and dish‐like scars.

Agreed upon intervention:
Most panelists (55%) selected hyperpigmentation
targeted lasers for treating this patient: NAFL being the
most frequently selected device (30%) and fractional
picosecond laser came in second place (21%).
Additional possible measures suggested by some
panelists:
• Thirty percent would combine topical medication for
improving color complexity including tretinoin, glycolic acid 30%, hydroquinone, or bimatoprost.
• IPL, AFL, and PDL were selected each by 13% of
panelists.
Patient 6: Female, Fitzpatrick skin type 3, moderately
atrophic dish‐like erythematous scars.

Agreed upon intervention:
Almost 60% of panelists favored using a vascular
laser (mostly PDL).
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Additional possible measures suggested by some
panelists:
• Most of the panelists will combine the vascular laser
with other EBD to address atrophic scars: 39% selected NAFL and 34% selected AFL.
• A surgical technique (punch biopsy/subcision/excision) and ﬁllers (including PLLA) were also suggested in combination with EBD (each by 13% of
panelists).
Patient 8: Male, Fitzpatrick skin type 3, extra‐facial
broad atrophic scars on the upper back.
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Seventy‐three percent of the panelists favored using intralesional/LAD corticosteroids or 5‐FU as part of the
treatment plan for this patient.
Additional possible measures suggested by some
panelists:
• Three suggested using the non‐fractional fully ablative
mode of CO2 laser to address the persistent elevated
parts.
• PDL combined with AFL or IL corticosteroids/5‐FU
injections was selected by 17% of the panelists.
Patient 10: Male, Fitzpatrick skin type 2, punched‐
out deep atrophic scars.

Agreed upon intervention:
Suggestions for treating this extra‐facial area were
divided almost equally between AFL (47%) and NAFL
(39%) by panelists.
Additional possible measures suggested by some
panelists:
• Twenty‐six percent suggested combining a ﬁller
(mostly PLLA or Proﬁllo) as LAD or using Enerjet.
• Glycolic acid peel 30% or 70% was suggested by two
experts.
Patient 9: Male, Fitzpatrick skin type 2, hyperplastic
papular scars.

Agreed upon intervention:
• The large majority of the panelists (77%) selected AFL.
• Surgical procedures were suggested to performed immediately before AFL at the same session or before
AFL session.
• Fifty‐two percent and 43% of experts favored using a
surgical technique (punch biopsy/subcision/excision)
or a ﬁller injection (including PLLA), respectively, for
mitigating these scars as sole procedure or in combination with AFL.
Additional possible measures suggested by some panelists:

Agreed upon intervention:
Most responders (69%) selected AFL as their EBD of
choice for this scar type, usually combined with LAD of
corticosteroids or 5‐FU in 60% of those choosing AFL.

• Some (17%) favored using NAFL with the above
combination.
• Cross TCA.
• RF devices.
Patient 11: Male, Fitzpatrick skin type 3, extra‐facial
broad keloidal scars on the upper chest.
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2.

3.

Agreed upon intervention:
• Most responders (69%) favored using intralesional
corticosteroids alone or in combination with 5‐FU for
treating these acne keloid scars.

4.

5.

Additional possible measures suggested by some
panelists:
• AFL was the most selected device for this patient
(43%) mostly used as for LAD of TAC/5‐FU.
• PDL was the next most suggested device in combination of AFL, intralesional TAC/5‐FU, or both.
• Some experts (13%) suggested using surgical techniques (speciﬁcally Z‐plasty).
• Fifty‐two percent and 43% of experts favored using a
surgical technique (punch biopsy/subcision/excision)
or ﬁller injection (including PLLA), respectively, for
mitigating these scars as sole procedure or in combination with AFL.
• Some experts (17%) favored using NAFL with the
above combination.

6.

7.

8.

CONSENSUS
RECOMMENDATIONS SUMMARY
The current published data in the ﬁeld of acne scar treatment is vastly limited, including the lack of large, well‐
controlled multicenter comparative trials of various laser
and energy treatments for acne scars. Such trials would be
helpful in establishing the relative utility and persistence of
beneﬁt of various laser treatments and also in comparing
their effectiveness versus that of nonenergy treatments.
Randomized studies comparing bundles of modalities, sets
of so‐called combination treatments, would also be helpful,
as these are most common in actual clinical practice. These
limitations, notwithstanding, the current recommendations
are based on a large volume of observational data and high
level of expert consensus. The following consensus statements are most useful in guiding clinical care when the
high‐level evidence is lacking, as in this current case.

9.

10.

11.

12.
13.

1. Seventy percent of panel members indicated that patients with active acne and acne scars should be treated

with EBD and topical or systemic medications in
parallel. The rational is to reduce the severity and/or
duration of inﬂammation and scarring potential and
enhance the effectiveness of topical or oral medication.
Vascular lasers were the preferred EBD in the management of inﬂammatory acne (84% of panelists)
with 595‐nm PDL being the most selected platform
(79% of panelists).
Panel members are unanimous in their view that EBDs
have a role in the management of acne scars, with
AFLs, NAFLs, vascular lasers, and RF devices preferentially selected by 70%–90% of the panel experts.
Most panel experts (86%) indicated that parallel
treatment with vascular, AFL, or NAFL and oral
antibiotics can have a positive synergistic effect on
inﬂammatory acne.
The majority of panelists (86%) indicate that EBDs
may be safely used concurrently with isotretinoin in
the appropriate setting. Most panelists (84%) selected vascular lasers as their preferred EBD for
patients who were being treated with isotretinoin.
Approximately three‐fourths of these reported adjusting vascular laser settings including decreasing
the pulse energy and number of passes in the setting
of isotretinoin use. Sixty percent and 45% of the
panelists supported the use of NAFL and AFL, respectively, during isotretinoin treatment.
EBDs were considered a ﬁrst‐line treatment of acne
scars for the following scar types: macular discoloration (95%); mild atrophic scarring (i.e., rolling
scarring, 73%); and moderate atrophic scarring (i.e.,
superﬁcial box car scarring, 78%).
For atrophic acne scars, panelists selected superﬁcial
boxcar scars (91%) as the most likely to respond to
EBD treatment.
The platforms used for each acne scar subtype are
highlighted in Table 1.
In the absence of contraindications, 95% of panelists
will continue laser treatment until the desired effect is
achieved, or improvement plateaus, rather than adhere to a predetermined number of treatments.
Considering AFL, 47% of panelists indicated that
the fractionated CO2 laser is more effective than the
fractionated Er:YAG for acne scarring, (91%) expected to perform a series of 2–4 AFL treatments to
achieve a satisfactory clinical response and preferred interval between treatment ranged from 2 to
6 months.
The majority of panelists favored moderate‐to‐high
pulse energy and low‐to‐moderate density in treating
acne scars with AFL. See Table 2 for relative density
and pulse settings for a common AFL.
Most panelists (90%) expect to perform 4–8 NAFL
treatments to achieve a satisfactory clinical response.
The preferred standard settings for NAFL in the
treatment of atrophic acne scars were moderate to
high pulse energy and low to moderate density.
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14. Considering vascular lasers, 95% indicated that
EBDs are a ﬁrst‐line treatment for erythematous ﬂat
acne scars.
15. Vascular lasers were the EBD of choice among most
panelists (52%) for hypertrophic acne scars. PDL
was the preferred vascular‐speciﬁc laser for 73% of
panelists, who also tended to use shorter pulse
durations in this setting.
16. More than 91% of the respondents indicated the
need for at least 3–6 vascular laser sessions for typical erythematous hypertrophic acne scars.
17. The vast majority of panelists (91%) combine multiple
EBD platforms, and other treatment modalities, in
the same treatment session. There is no “cookbook”
approach as a treatment plan is based on multiple
factors unique to a particular patient on a particular
day such as scar types, co‐existing conditions, prior
treatments and response, skin type and degree of
melanization, and tolerance for pain and downtime.
18. When combining EBDs, most panelists (84%) recommended the combination of PDL and fractional lasers. When this combination is used the
vascular laser should generally be applied ﬁrst
since fractional lasers are associated with immediate tissue reactions that could impact vascular
laser treatment. Three‐quarters of panelists do not
adjust EBD settings when using multiple platforms
in the same session.
19. More than 73% of panelists reported using tissue
ﬁllers or biostimulators with EBDs as part of acne
scar treatment. Of these approximately 70% reported
a preference for using HA‐based ﬁllers.
20. There was nearly complete consensus (95%) for
combining EBD (mainly PDL) with intralesional
and/or LAD of 5‐FU and/or TAC for treating hypertrophic acne scars.
21. In patients with darker skin types (Fitzpatrick phototype III–VI) presenting with atrophic boxcar acne
scars, the majority of panel members (73%) selected
NAFL as their preferred EBD. FRF devices were
the next highest choice (39%—some panelists selected both).
22. Regarding NAFL parameter modiﬁcations in patients with darker skin types, almost 70% of panelists
reported decreasing density.
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